435
Participants
Start Date
April 30, 2006
Primary Completion Date
May 31, 2008
Study Completion Date
December 31, 2014
Pazopanib
Oral pazopanib tablet 800 mg once daily continuously
placebo
matching placebo (800 mg tablet) once daily
GSK Investigational Site, Tallaght, Dublin
GSK Investigational Site, Tunis
GSK Investigational Site, Tunis
GSK Investigational Site, Vienna
GSK Investigational Site, Islamabad
GSK Investigational Site, Quilmes
GSK Investigational Site, St Leonards
GSK Investigational Site, Waratah
GSK Investigational Site, Sfax
GSK Investigational Site, Heidelberg
GSK Investigational Site, Wodonga
GSK Investigational Site, San Miguel de Tucumán
GSK Investigational Site, Sousse
GSK Investigational Site, Palmerston North
GSK Investigational Site, Córdoba
GSK Investigational Site, Newtown, Wellington
GSK Investigational Site, Hobart
GSK Investigational Site, Christchurch
GSK Investigational Site, Orbassano (TO)
GSK Investigational Site, Tallinn
GSK Investigational Site, Prague
GSK Investigational Site, Rozzano (MI)
GSK Investigational Site, Milan
GSK Investigational Site, Crema
GSK Investigational Site, Pátrai
GSK Investigational Site, Casalpusterlengo (LO)
GSK Investigational Site, Tartu
GSK Investigational Site, Lahore
GSK Investigational Site, Kharkiv
GSK Investigational Site, Zaporizhzhya
GSK Investigational Site, Karachi
GSK Investigational Site, Lviv
GSK Investigational Site, Donetsk
GSK Investigational Site, Mérida
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Yaroslavl
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Voronezh
GSK Investigational Site, Mumbai
GSK Investigational Site, Kazan'
GSK Investigational Site, Samara
GSK Investigational Site, Chelyabinsk
GSK Investigational Site, Hyderabad
GSK Investigational Site, Bangalore
GSK Investigational Site, Omsk
GSK Investigational Site, Trivandrum
GSK Investigational Site, Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Capital Federal
GSK Investigational Site, Rosario
GSK Investigational Site, Salzburg
GSK Investigational Site, Vienna
GSK Investigational Site, Vienna
GSK Investigational Site, Belo Horizonte
GSK Investigational Site, Porto Alegre
GSK Investigational Site, Jaú
GSK Investigational Site, Viña del Mar
GSK Investigational Site, Brno
GSK Investigational Site, Chomutov
GSK Investigational Site, Ostrava - Poruba
GSK Investigational Site, Athens
GSK Investigational Site, Athens
GSK Investigational Site, Athens
GSK Investigational Site, Athens
GSK Investigational Site, Thessaloniki
GSK Investigational Site, Hong Kong
GSK Investigational Site, Kowloon
GSK Investigational Site, Tuen Mun, New Territories
GSK Investigational Site, Galway
GSK Investigational Site, Pune
GSK Investigational Site, Rome
GSK Investigational Site, Rome
GSK Investigational Site, Riga
GSK Investigational Site, Kaunas
GSK Investigational Site, Klaipėda
GSK Investigational Site, Vilnius
GSK Investigational Site, Guadalajara
GSK Investigational Site, Mexico City
GSK Investigational Site, Gdansk
GSK Investigational Site, Krakow
GSK Investigational Site, Krakow
GSK Investigational Site, Olsztyn
GSK Investigational Site, Olsztyn
GSK Investigational Site, Poznan
GSK Investigational Site, Warsaw
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Bratislava
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Songpa-gu, Seoul
GSK Investigational Site, Kyiv
GSK Investigational Site, Exeter
GSK Investigational Site, Manchester
GSK Investigational Site, Bebington, Wirral
GSK Investigational Site, Belfast
GSK Investigational Site, Swansea
Lead Sponsor
GlaxoSmithKline
INDUSTRY